Universal CAR-T Cell Therapy for Refractory Lupus Nephritis

Inclusion Criteria

• •Aged 18-65 years; both genders eligible.
• •Subjects diagnosed with lupus nephritis.
• •Previous treatment outcomes were unsatisfactory.
• •Diagnosis of active nephritis type III or IV with or without type V according to 2018 International Society of Nephrology and Society of Renal Pathology (ISN/RPS) criteria.
• •NIH Activity Index \> 2 and elevated chronicity index.
• •Urine protein: creatinine ratio (UPCR) ≥ 1.0 g/g, or 24-hour urine protein ≥ 1.0 g, with or without active urine sediment with red blood cell casts.
• •Receiving hormones with or without antimalarials.
• •SLEDAI-2K score ≥ 6.
• •Antinuclear antibody positive, and/or anti-ds-DNA antibody positive, and/or anti-Smith antibody positive.
• •Positive expression of CD19 on B cells in peripheral blood.
• •Agrees to use double barrier methods, condoms, oral or injectable contraceptives, or intrauterine devices during the study period and for one year after taking the study medication.
• •Provides written informed consent.